NEW YORK (GenomeWeb News) - Genesis Genomics has received a CAN$311,735 (US$ 305,540) investment from the Ontario provincial government to fund its mitochondrial DNA-based diagnostic tests for cancer, the firm’s controller, Carole McCollum, told GenomeWeb News today.

 

The Thunder Bay, Ontario-based company will use the funds from the Northern Ontario Heritage Fund to continue to develop and commercialize a diagnostic test for prostate cancer and to develop an early-stage breast cancer test, McCollum said.